Regorafenib: A New Indication
Results of clinical trials of regorafenib for treatment of progressive hepatocellular carcinoma have been published.
This drug was developed by Bayer and approved for treatment of metastatic colorectal cancer and gastrointestinal stromal tumors. Now it has passed tests for effectiveness in the treatment of progressive hepatocellular carcinoma. The trials involved 573 patients with progressive hepatocellular carcinoma, who earlier received sorafenib (including 194 patients in the placebo group). The survival in the regorafenib group was 10.6 months, while in the placebo group it was <8 months.
Tumor size reduction to minimum dimensions was observed in two patients in the regorafenib group.